Mark Goldsmith, Revolution Medicines CEO
July 9, 2025 08:00 AM EDT
Deals
AI

Rev­o­lu­tion and Iambic to com­bine da­ta and AI mod­els in R&D deal for can­cer drugs

Andrew Dunn

Senior Biopharma Correspondent

Rev­o­lu­tion Med­i­cines has be­come one of the in­dus­try’s most valu­able pre-com­mer­cial com­pa­nies thanks to its pipeline of clin­i­cal-stage can­cer drugs. CEO Mark …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Who pays the most in bio­phar­ma? We an­a­lyzed me­di­an pay at 177 com­pa­nies

Up­dat­ed: Mer­ck drops $10B for res­pi­ra­to­ry drug­mak­er Verona Phar­ma in its first ac­qui­si­tion of 2025

Fed­er­al judge sides with FDA on its mifepri­s­tone safe­ty pro­gram

Bio­phar­ma's 20 high­est-paid CEOs of 2024 with $20M+ pay­days

Q&A: Re­tir­ing Arv­inas CEO John Hous­ton talks PRO­TACs, in­vestor con­fi­dence and what’s next with Pfiz­er

sponsored

Un­cov­er­ing the Po­ten­tial of Tar­get­ing the CD38 Path­way for Im­mune-Me­di­at­ed Dis­eases

A service from the Financial Times